Drugs / Amblyomin-X
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03120130 | Feb → Aug 2021 | cancer of unknown primary site | Uniao Quimica | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amblyomin-X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03120130 ↗ |
| Action | Inhibit | “Amblyomin-X is an inhibitor of Factor Xa” NCT03120130 ↗ |
| Route | Intravenous | “The patient will receive the intravenous drug.” NCT03120130 ↗ |